DJSG
TTNP

D.J. St. Germain’s Titan Pharmaceuticals TTNP Stock Holding History

D.J. St. Germain’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1 Hold
1
– – ﹤0.01% 914
2026
Q1 		$1 Hold
1
– – ﹤0.01% 901
2025
Q4 		$2 Hold
1
– – ﹤0.01% 924
2025
Q3 		$5 Hold
1
– – ﹤0.01% 899
2025
Q2 		$4 Hold
1
– – ﹤0.01% 880
2025
Q1 		$4 Hold
1
– – ﹤0.01% 802
2024
Q4 		$3 Hold
1
– – ﹤0.01% 830
2024
Q3 		$5 Hold
1
– – ﹤0.01% 770
2024
Q2 		$6 Hold
1
– – ﹤0.01% 774
2024
Q1 		$7 Buy
+1
New +$7 ﹤0.01% 782
2023
Q4 		– Hold
0
– – – 821
2023
Q3 		– Hold
0
– – – 778
2023
Q2 		– Hold
0
– – – 729

Other funds holding TTNP

CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
BWL
Bogart Wealth LLC Mclean, Virginia $2.92B AUM 23.85% 1-Year Est. Return
CSC
Caldwell Sutter Capital Sausalito, California $265M AUM 30.15% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

D.J. St. Germain's TTNP Position: Q2 2026 in Review

D.J. St. Germain held its Titan Pharmaceuticals (TTNP) position steady in Q2 2026 at 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #914.

D.J. St. Germain first reported a position in TTNP in Q1 2024 and has held it in 10 quarters since. The position peaked at $7 in Q1 2024. 5 funds tracked by Wall St. Rank hold TTNP as of Q2 2026.

  • D.J. St. Germain held 1 share of Titan Pharmaceuticals worth $1 as of Q2 2026.
  • D.J. St. Germain left its Titan Pharmaceuticals share count unchanged in Q2 2026.
  • Titan Pharmaceuticals made up ﹤0.01% of D.J. St. Germain's portfolio in Q2 2026, its #914 holding.
  • D.J. St. Germain first reported a position in Titan Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • D.J. St. Germain's Titan Pharmaceuticals position peaked at $7 in Q1 2024.
  • 5 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q2 2026.

Based on D.J. St. Germain's 13F filing for Q2 2026, filed 21 Jul 2026.